← Back to Search

Monoclonal Antibodies

Tivozanib for Liver Cancer (DEDUCTIVE Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by AVEO Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 18 years old
Histologically or cytologically or radiologically confirmed unresectable locally advanced or metastatic hepatocellular carcinoma. Measurable or evaluable disease by RECIST 1.1 criteria. Patients can be either untreated or have progressed on both bevacizumab and atezolizumab or both bevacizumab and atezolizumab in combination with a second immune checkpoint inhibitor.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 24 months
Awards & highlights

DEDUCTIVE Trial Summary

This trial will study whether the combination of tivozanib and durvalumab is safe and tolerated in people with advanced HCC, as well as whether the combination has preliminary anti-tumor activity.

Eligible Conditions
  • Liver Cancer

DEDUCTIVE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

DEDUCTIVE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment Emergent Adverse Events (TEAEs)
Secondary outcome measures
Overall Survival (OS)
Progression Free Survival (PFS)
Response Rate (Objective Response Rate)

Side effects data

From 2014 Phase 3 trial • 277 Patients • NCT01076010
25%
Hypertension
14%
Diarrhoea
13%
Fatigue
12%
Asthenia
10%
Palmar-plantar erythrodysaesthesia syndrome
6%
Cough
6%
Decreased appetite
6%
Dysphonia
6%
Dyspnoea
2%
Neoplasm progression
2%
Renal cancer
2%
Anaemia
1%
Metastases to soft tissue
1%
General physical health deterioration
1%
Apnoea
1%
Hypokalaemia
1%
Bone pain
1%
Bronchitis
1%
Hypercalcaemia
1%
Metastases to pleura
1%
Pathological fracture
1%
Metastases to the mediastinum
1%
Pleural effusion
1%
Pneumothorax
1%
Acute myocardial infarction
1%
Aortic aneurysm
1%
Pulmonary embolism
1%
Death
1%
Multi-organ failure
1%
Hypoglycaemia
1%
Cerebral infarction
1%
Transient ischaemic attack
1%
Pelvic venous thrombosis
1%
Body temperature increased
1%
Cardiopulmonary failure
1%
Myocardial infarction
1%
Cardiac failure
1%
Respiratory failure
1%
Arteriosclerosis coronary artery
1%
Cardio-respiratory arrest
1%
Delusional disorder, somatic type
1%
Pleurisy
1%
Ischaemic stroke
1%
Bile duct stone
1%
Cholangitis
1%
Jaundice cholestatic
1%
Sepsis
1%
Myxoedema
1%
Pancreatitis acute
1%
Vena cava thrombosis
1%
Skin lesion
1%
Head injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sorafenib Crossover to Tivozanib
First Line Tivozanib
First Line Sorafenib

DEDUCTIVE Trial Design

1Treatment groups
Experimental Treatment
Group I: Tivozanib in Combination with DurvalumabExperimental Treatment2 Interventions
Tivozanib in Combination with Durvalumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tivozanib
FDA approved
Durvalumab
FDA approved

Find a Location

Who is running the clinical trial?

AstraZenecaIndustry Sponsor
4,242 Previous Clinical Trials
288,525,201 Total Patients Enrolled
2 Trials studying Liver Cancer
1,040 Patients Enrolled for Liver Cancer
AVEO Pharmaceuticals, Inc.Lead Sponsor
45 Previous Clinical Trials
3,923 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What areas are hosting this clinical research?

"There are currently 12 clinical trial sites participating in this study, located in Seattle, Tyler and Orange. Patients should select the closest location to them to reduce travel burden if they decide to enrol."

Answered by AI

How many participants are being admitted to this experiment?

"Unfortunately, recruitment for this trial is no longer ongoing. It was initially posted on September 30th 2019 and last updated November 17th 2022. However, there are currently 2608 studies enrolling patients with carcinoma hepatocellular and 336 trials recruiting participants to investigate Tivozanib's efficacy."

Answered by AI

Are there vacancies in this investigation for potential participants?

"Unfortunately, this clinical trial is no longer recruiting individuals. The initial posting date was September 30th 2019 and the last edit happened on November 17th 2022. Other trials actively seeking patients with carcinoma and hepatocellular diseases are available; 2608 studies in total, while there are 336 studies searching for participants to take Tivozanib."

Answered by AI

Have there been other experiments involving Tivozanib?

"Initially studied in 2010, tivozanib has been subject to 128 clinical trials. Currently there are 336 active studies, with a significant presence in Seattle, Washington."

Answered by AI

What maladies can Tivozanib effectively combat?

"Physicians regularly administer Tivozanib to those undergoing neoadjuvant systemic therapy. Additionally, the drug can be beneficial in treating KRN 951, renal cell carcinoma, and various advanced directives."

Answered by AI
~5 spots leftby Mar 2025